Systems pharmacology-based identification of pharmacogenomic determinants of adverse drug reactions using human iPSC-derived cell lines

Baker, 2004, The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada, Can Med Assoc J, 170, 1678, 10.1503/cmaj.1040498 Ferri, 2013, Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity, Pharmacol Ther, 138, 470, 10.1016/j.pharmthera.2013.03.005 Phillips, 2001, Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review, JAMA, 286, 2270, 10.1001/jama.286.18.2270 Morel, 2006, Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance, Mol Cancer Ther, 5, 10.1158/1535-7163.MCT-06-0327 Ozeki, 2011, Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population, Hum Mol Genet, 20, 1034, 10.1093/hmg/ddq537 2008, SLCO1B1 variants and statin-induced myopathy — a genomewide study, N Engl J Med, 359, 789, 10.1056/NEJMoa0801936 Becquemont, 2009, Pharmacogenomics of adverse drug reactions: practical applications and perspectives, Pharmacogenomics, 10, 961, 10.2217/pgs.09.37 Wei, 2012, Pharmacogenomics of adverse drug reactions: implementing personalized medicine, Hum Mol Genet, 21, 10.1093/hmg/dds341 Carcamo-Orive, 2016, Analysis of transcriptional variability in a large human iPSC library reveals genetic and non-genetic determinants of heterogeneity, Cell Stem Cell, 10, e1001301 Lo Sardo, 2016, Influence of donor age on induced pluripotent stem cells, Nat Biotechnol, 35, 69, 10.1038/nbt.3749 Denning, 2016, Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform, Biochim Biophys Acta – Mol Cell Res, 1863, 1728, 10.1016/j.bbamcr.2015.10.014 Shinozawa, 2017, Recapitulation of clinical individual susceptibility to drug-induced QT prolongation in healthy subjects using iPSC-derived cardiomyocytes, Stem Cell Rep, 8, 226, 10.1016/j.stemcr.2016.12.014 Matsa, 2014, Human stem cells for modeling heart disease and for drug discovery, Sci Transl Med, 6, 10.1126/scitranslmed.3008921 Stillitano, 2017, Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells, Elife, 6, 10.7554/eLife.19406 Burridge, 2016, Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity, Nat Med, 22, 547, 10.1038/nm.4087 Gao, 2017, A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better in vitro model of hepatotoxicity than most hepatoma cell lines, Cell Biol Toxicol, 10.1007/s10565-017-9383-z Takasato, 2015, Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis, Nature, 526, 564, 10.1038/nature15695 Kratochwil, 2017, Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling, AAPS J, 19, 534, 10.1208/s12248-016-0019-7 Stokes, 2015, Physiome-on-a-Chip: the challenge of “scaling” in design, operation, and translation of microphysiological systems, CPT Pharmacomet Syst Pharmacol, 4, 559, 10.1002/psp4.12042 Esch, 2011, The role of body-on-a-chip devices in drug and toxicity studies, Annu Rev Biomed Eng, 13, 55, 10.1146/annurev-bioeng-071910-124629 Solomon, 2015, Banking on iPSC- is it doable and is it worthwhile. Stem cell rev, Reports, 11, 1 Bai, 2013, Systems pharmacology to predict drug toxicity: integration across levels of biological organization, Annu Rev Pharmacol Toxicol, 53, 451, 10.1146/annurev-pharmtox-011112-140248 Verbist, 2015, Using transcriptomics to guide lead optimization in drug discovery projects: lessons learned from the QSTAR project, Drug Discov Today, 20, 505, 10.1016/j.drudis.2014.12.014 Kohler, 2017, Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine, Eur J Pharm Sci, 10.1016/j.ejps.2017.05.018 Zielinski, 2015, Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis, Nat Commun, 6, 7101, 10.1038/ncomms8101 Iyengar, 2012, Merging systems biology with pharmacodynamics, Sci Transl Med, 4, 10.1126/scitranslmed.3003563 Zhao, 2012, Systems pharmacology: network analysis to identify multiscale mechanisms of drug action, Annu Rev Pharmacol Toxicol, 52, 505, 10.1146/annurev-pharmtox-010611-134520 van Hasselt, 2015, Towards integrative systems pharmacology models in oncology drug development, Drug Discov Today Technol, 15, 1, 10.1016/j.ddtec.2015.06.004 Zhao, 2013, Systems pharmacology of adverse event mitigation by drug combinations, Sci Transl Med, 5, 10.1126/scitranslmed.3006548 Berger, 2010, Systems pharmacology of arrhythmias, Sci Signal, 3, 10.1126/scisignal.2000723 Yamamoto, 2017, A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations, Pharm Res, 34, 333, 10.1007/s11095-016-2065-3 van Hasselt, 2015, Disease progression/clinical outcome model for castration-resistant prostate cancer in patients treated with eribulin, CPT Pharmacomet Syst Pharmacol, 4, 386, 10.1002/psp4.49 van Hasselt, 2013, Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate associated neutropenia, Br J Clin Pharmacol, 76, 2878, 10.1111/bcp.12143 Altman, 2017, Artificial intelligence (AI) systems for interpreting complex medical data sets, Clin Pharmacol Ther, 10.1002/cpt.650 Eduati, 2015, Prediction of human population responses to toxic compounds by a collaborative competition, Nat Biotechnol, 33, 933, 10.1038/nbt.3299 Force, 2007, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition, Nat Rev Cancer, 7, 332, 10.1038/nrc2106 Sala, 2016, Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?, Br J Pharmacol Tromp, 2017, Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction, Clin Pharmacol Ther, 10.1002/cpt.614 Sharma, 2017, High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells, Sci Transl Med, 9, 10.1126/scitranslmed.aaf2584 Tylutki, 2017, A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application, Sci Rep, 7, 39494, 10.1038/srep39494 van Hasselt, 2011, Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity, Clin Pharmacol Ther, 90, 126, 10.1038/clpt.2011.74 van Hasselt, 2012, Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab, Pharm Res, 29, 3499, 10.1007/s11095-012-0845-y Han, 2017, Targeted next-generation sequencing for comprehensive genetic profiling of pharmacogenes, Clin Pharmacol Ther, 101, 396, 10.1002/cpt.532 Ohara, 2017, Modeling drug-induced neuropathy using human iPSCs for predictive toxicology, Clin Pharmacol Ther, 101, 754, 10.1002/cpt.562 Kim, 2016, HDAC6 inhibitors rescued the defective axonal mitochondrial movement in motor neurons derived from the induced pluripotent stem cells of peripheral neuropathy patients with HSPB1 mutation, Stem Cells Int, 2016, 1 Ware, 2015, Prediction of drug-induced liver injury in micropatterned Co-cultures containing iPSC-derived human hepatocytes, Toxicol Sci, 145, 252, 10.1093/toxsci/kfv048 Itoh, 2011, Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells, Proc Natl Acad Sci U S A, 108, 8797, 10.1073/pnas.1100332108 Itoh, 2013, Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs), PLoS One, 8, 10.1371/journal.pone.0077673 Spence, 2010, Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro, Nature, 470, 105, 10.1038/nature09691